Importantly, we also discovered that selective HDAC2 inhibitor effectively ameliorates HCC malignancy by reducing tumor volume, significantly inhibiting HCC tumor formation and attenuating HCC autophagy in vivo. This evidence concerns the gene HDAC2 and hepatocellular carcinoma.